Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Net Income: 2012-2024

Historic Net Income for Theravance Biopharma (TBPH) over the last 13 years, with Dec 2024 value amounting to -$64.0 million.

  • Theravance Biopharma's Net Income rose 128.47% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.8 million, marking a year-over-year increase of 144.15%. This contributed to the annual value of -$64.0 million for FY2024, which is 15.94% down from last year.
  • Latest data reveals that Theravance Biopharma reported Net Income of -$64.0 million as of FY2024, which was down 15.94% from -$55.2 million recorded in FY2023.
  • In the past 5 years, Theravance Biopharma's Net Income registered a high of $1.1 billion during FY2022, and its lowest value of -$64.0 million during FY2024.
  • Moreover, its 3-year median value for Net Income was -$55.2 million (2023), whereas its average is $341.6 million.
  • Per our database at Business Quant, Theravance Biopharma's Net Income surged by 1,642.60% in 2022 and then plummeted by 104.82% in 2023.
  • Yearly analysis of 5 years shows Theravance Biopharma's Net Income stood at $16.8 million in 2020, then skyrocketed by 290.60% to $65.6 million in 2021, then spiked by 1,642.60% to $1.1 billion in 2022, then plummeted by 104.82% to -$55.2 million in 2023, then dropped by 15.94% to -$64.0 million in 2024.